Sarepta Therapeutics Inc. is developing new patient information to potentially help gain European approval for its Duchenne muscular dystrophy treatment Exondys 51 (eteplirsen) and possibly help make headway with payers.
Controversially granted accelerated approval by FDA in September, Exondys 51 has been submitted to the European Medicines Agency for conditional approval, Sarepta CEO and CMO Edward Kaye said during a...